Current and Novel Therapeutic Strategies for Cancers in the Era of Personalized Treatment
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (13 May 2022) | Viewed by 8583
Special Issue Editors
Interests: cancer cells; cancer research; oncology;cell culture;cell proliferation;colorectal cancer ;cancer biology;cell signaling;apoptosis;signaling pathways
Special Issues, Collections and Topics in MDPI journals
Interests: cancer therapy;cancer cells;colorectal cancer;tumors;oncology;cancer research; kinase inhibitors;cancer biology
Special Issues, Collections and Topics in MDPI journals
Interests: cancer research; tumors; cancer cells; cancer; cancer biomarkers;tumor biolo-gy;cancer biology;clinical oncology;metastasis;cancer immunology
Special Issue Information
Dear Colleagues,
This Special Issue of Life is dedicated to personalized medicine in cancer. The therapeutic strategies currently approved for the treatment of solid tumors include multidisciplinary approaches: surgery, radiotherapy and medical treatment. Over the past decade, huge progress has derived from the introduction of target therapies, immunotherapy and other novel approaches such as epigenetic drugs that have paved the way to more tailored opportunities for cancer treatment. Unfortunately, a high portion of patients with cancer still present poor outcomes, due to the complex molecular heterogeneity of tumors and multiple mechanisms driving therapeutic resistance. In oncology, the use of personalized medicine is the main goal, to transform traditional medical chemotherapy-based anti-cancer treatments into molecularly driven, individualized anti-cancer therapies, based on results from molecular analyses that have entered the mainstream of clinical practice in cancer. Whole DNA sequencing technologies such as next generation sequencing (NGS) have improved the genomic understanding of disease; nevertheless, a multi-omic approach that involves the study of the transcriptome, proteome and metabolome is strongly suggested, to further stratify patients and provide deeper insights into cancers. With this Special Issue, we aim to collect original data from translational research groups and updated reviews of the literature to highlight recent discoveries on personalized medicine in the field of cancer.
Dr. Giulia Martini
Dr. Stefania Napolitano
Dr. Carminia Maria Della Corte
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- cancer
- personalized medicine
- multi-omic
- translational research
- individualized treatment
